Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BMS 986141

Next Previous
X
Search
Drug Profile

BMS 986141

Alternative Names: BMS-986141; UDM-003183

Latest Information Update: 15 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb; Institute for Research in Immunology and Cancer - Commercialization of Research
  • Developer Bristol-Myers Squibb
  • Class Antithrombotics; Benzamides; Benzofurans; Ethers; Imidazoles; Small molecules; Thiadiazoles; Thiazoles
  • Mechanism of Action PAR-4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Thrombosis

Most Recent Events

  • 25 Mar 2022 Phase-II clinical trials in Thrombosis in United Kingdom (PO) (NCT05093790)
  • 26 Oct 2021 Bristol-Myers Squibb plans a phase IIa trial for Coronary artery disease (Combination therapy) in the United Kingdom, in October 2021 (NCT05093790)
  • 01 Oct 2021 Chemical structure information added

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top